Agenus Inc. (AGEN)
Symbol Info
Listed Symbol AGEN
Name Agenus Inc.
Share Info
Annual Info
Latest Fiscal Dividend Per Share $-
Latest Fiscal Date 2018-12-31
Latest Fiscal Revenue $19,474,672
Latest Fiscal EPS $-1.46
Price Info
21 Day Moving Average $2.7605
21 Day EMA $2.711730
50 Day Moving Average $2.7742
50 Day EMA $2.752680
200 Day EMA $2.771300
200 Day Moving Average 2.864250
52 Week High $3.88
52 Week Low $1.54
52 Week Change $31.500000
Alpha 0.006937
Beta 1.8204
Standard Deviation 0.213055
R2 0.086183
Periods 60
Share Information
10 Day Average Volume 793,953
20 Day Average Volume 803,066
30 Day Average Volume 790,002
50 Day Average Volume 858,155
Outstanding Shares 137,312,825
Float Shares 129,580,212
Percent Float 94.37%
Short Interest -
Short Percent Float -
Short Interest Ratio -
Short Date
Holders
Institutions 202
Institute Holdings Date 2019-09-30
Institute Bought Previous 3 Months 5,295,494
Institute Holdings Percent 46.900000
Institute Sold Previous 3 Months 4,009,927
Insider Holdings Date 2019-08-31
Insider Bought Previous 3 Months 32
Insider Holdings Percent 5.60%
Insider Sold Previous 3 Months -
Insiders Shares Owned 7,732,613
Price Change
7 Day Price Change $0.0700002
7 Day Percent Change 2.73%
21 Day Price Change $-0.3999999
21 Day Percent Change -13.20%
30 Day Price Change $-0.4699998
30 Day Percent Change -15.16%
Month To Date Price Change $0.0500
Month To Date Percent 1.94%
90 Day Price Change $-0.1
90 Day Percent Change -3.66%
Quarter To Date $0.050000
Quarter To Date Percent 1.94%
180 Day Price Change $-0.01
180 Day Percent Change -0.38%
200 Day Price Change $-0.2
200 Day Percent Change -7.07%
Year To Date $0.250000
Year To Date Percent 10.50%
Profile
Description Agenus Inc is an American biotechnology company. Its main target is immuno-oncology treatments. The company's portfolio consists of therapeutic antibodies and vaccines to treat immuno-oncology illnesses: cancers, shingles, malaria, glioblastoma, and others. Agenus treatments aim, by combining multiple antibody platforms, to stimulate the immune system to recognize and fight cancer cells. The company has been cooperating with companies like Incyte, Merck Sharp & Dohme, and Recepta Biopharma to achieve over a dozen antibody programs. Some of its products include Prophage, AutoSynVax, QS-21 Stimulon, and others.
Details
Issue Type CS
Market Cap $361,132,730
Sec Type EQS
Auditor KPMG LLP
Total Shares Outstanding 137,312,825
CEO Garo H Armen
Employees 294
Last Audit UE
Classification
CIK 0001098972
Industry Biotechnology
Sector Healthcare
NAICS Biological Product (except Diagnostic) Manufacturing(325414)
Info
Address 3 Forbes Road
Lexington, MA 02421-7305
Website http://www.agenusbio.com
Facisimile +1 781 674-4200
Telephone +1 781 674-4400
Email investor@agenusbio.com
Key Ratios
Profitability
EBIT Margin -71.2
EBITDA Margin -65.6
Pre-Tax Profit Margin -453.9
Profit Margin Cont -
Gross Margin -
Profit Margin TOT -
Income Statements
Revenue $76,360,561
Revenue Per Share $0.5561
Revenue 3 Years $17.81
Revenue 5 Years $40.63
Valuation Measures
PE Ratio -
Enterprise Value $281,676,088
Price To Sales 4.729310
Price To Free Cash 202.600000
PE High Last 5 Years -
Price To Book 49.7
Price To Cash Flow 116.7
PE Low Last 5 Years -
Price To Tangible Book -1.8
Financial Strength
Total Debt To Equity -
Int Coverage -2.3
Current Ratio 1.1
Leverage Ratio -1.5
Quick Ratio 1.0
Long Term Debt To Capital -
Assets
Receivables Turnover 7.1
Invoice Turnover -
Assets Turnover 0.20
Management Effectiveness
Return Assets -66.86
Return On Equity 83.88
Return On Capital -
Dividends
Dividend 3 Years $-
Dividend 5 Years $-
Ex Dividend Date
Dividend Rate $-
Dividend Yield -
Payment Type


Your Recent History
NASDAQ
AGEN
Agenus
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.